Home › NDC Lookup › RxCUI directory › RxCUI 2720338

Clemastine fumarate 2.68 MG Oral Tablet [Clemsza] — RxCUI 2720338

RxNorm drug concept · Semantic branded drug
RxCUI 2720338 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2720338
Official nameClemastine fumarate 2.68 MG Oral Tablet [Clemsza]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asClemsza 2.68 MG Oral Tablet
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)74 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Clemastine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Clemastine is an antihistamine used to relieve the classic symptoms of allergies — sneezing, runny nose, itchy eyes, and watery eyes. It's also used to treat mild hives (urticaria)...
  • Yes — drowsiness is the most common side effect, and it can be significant. You should avoid driving, operating machinery, or anything that requires full alertness until you know h...
  • The oral solution (Clemastine Fumarate syrup) is indicated for children aged 6 through 12 for allergic rhinitis and hives. The tablet form has not been established as safe and effe...
  • Yes — let your doctor know if you have an enlarged prostate, trouble urinating, narrow-angle glaucoma, a stomach ulcer, or any bowel obstruction. These conditions can get worse wit...
📖 Read our full Clemastine guide →

🕸️ Concept Web — How Clemastine fumarate 2.68 MG Oral Tablet [Clemsza... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Clemastine fumarate 2.68 MG Oral Tablet [Clemsza] RxCUI 2720338

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Clemastine 2578
    • Clemastine fumarate 142430
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Clemsza 2720332
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Clemastine Oral Tablet 371549
    • Clemastine fumarate Oral Tablet 2646289
    • Clemastine Oral Product 1152773
    • Clemastine Pill 1152774
    • Clemastine fumarate Oral Product 2661104
    • Clemastine fumarate Pill 2660524
    • Clemastine Oral Tablet [Clemsza] 2720336
    • Clemastine fumarate Oral Tablet [Clemsza] 2720337
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Clemastine fumarate 2.68 MG Oral Tablet SCD · 857461
  • Clemastine fumarate 2.68 MG SCDC · 857460
  • Clemastine Oral Tablet SCDF · 371549
  • Clemastine fumarate Oral Tablet SCDFP · 2646289
  • Clemastine Oral Product SCDG · 1152773
  • Clemastine Pill SCDG · 1152774
  • Clemastine fumarate Oral Product SCDGP · 2661104
  • Clemastine fumarate Pill SCDGP · 2660524

Brand-Name Concepts

  • Clemastine fumarate 2.68 MG [Clemsza] SBDC · 2720333
  • Clemastine Oral Tablet [Clemsza] SBDF · 2720336
  • Clemastine fumarate Oral Tablet [Clemsza] SBDFP · 2720337
  • Clemsza Oral Product SBDG · 2720334
  • Clemsza Pill SBDG · 2720335
  • Clemsza BN · 2720332

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2720338 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
71085-0081-30 30 TABLET in 1 BOTTLE (71085-081-30) CLEMSZA IPG Pharmaceuticals, Inc. 2025-08-01
Observed labelers: IPG Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$3.3067
Range $3.3067–$3.3067 · middle 50% $3.3067–$3.3067 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.